Cargando…

Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis

INTRODUCTION: Microscopic bowel inflammation is present in up to 50% of patients with spondyloarthritis (SpA) and is associated with more severe disease. Currently no reliable biomarkers exist to identify patients at risk. Calprotectin is a sensitive marker of neutrophilic inflammation, measurable i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cypers, H, Varkas, G, Beeckman, S, Debusschere, K, Vogl, T, Roth, J, Drennan, M B, Lavric, M, Foell, D, Cuvelier, C A, De Vos, M, Delanghe, J, Van den Bosch, F, Elewaut, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941173/ https://www.ncbi.nlm.nih.gov/pubmed/26698844 http://dx.doi.org/10.1136/annrheumdis-2015-208025

Ejemplares similares

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
por: Carron, Philippe, et al.
Publicado: (2016)

Association of circulating calprotectin with lipid profile in axial spondyloarthritis
por: Genre, Fernanda, et al.
Publicado: (2018)

RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
por: Venken, Koen, et al.
Publicado: (2019)

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
por: Jarlborg, Matthias, et al.
Publicado: (2020)

Decreased fecal calprotectin levels in Spondyloarthritis patients colonized by Blastocystis spp.
por: Chaparro-Olaya, Jacqueline, et al.
Publicado: (2022)

Spondyloarthritis in the Democratic Republic of the Congo: a prospective hospital-based study
por: Lebughe, Pierrot, et al.
Publicado: (2018)

Calprotectin in inflammatory bowel disease
por: Khaki-Khatibi, Fatemeh, et al.
Publicado: (2020)

Fecal calprotectin in inflammatory bowel disease
por: Walsham, Natalie E, et al.
Publicado: (2016)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis
por: Huang, Jinxian, et al.
Publicado: (2017)

Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
por: Melis, Lode, et al.
Publicado: (2009)

Global prevalence of spondyloarthritis in low-income and middle-income countries: a systematic review and meta-analysis protocol
por: Allado, Edem, et al.
Publicado: (2020)

(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
por: Lambert, Bieke, et al.
Publicado: (2016)

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
por: Gherghe, Ana Maria, et al.
Publicado: (2015)

MRI of the axial skeleton in spondyloarthritis: the many faces of new bone formation
por: Laloo, Frederiek, et al.
Publicado: (2019)

PReS-FINAL-2340: A pathogenic role for S100A8/A9 in experimental autoimmune arthritis
por: Kessel, C, et al.
Publicado: (2013)

Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study
por: Nørgaard, M, et al.
Publicado: (2011)

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
por: Stouten, Veerle, et al.
Publicado: (2021)

Prostaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases
por: Karaky, Mohamad, et al.
Publicado: (2022)

Spondyloarthritis: How far are we from precision medicine?
por: So, Jacqueline, et al.
Publicado: (2022)

The Role of Fecal Calprotectin in Investigating Inflammatory Bowel Diseases
por: Erbayrak, Mustafa, et al.
Publicado: (2009)

Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease
por: Lamb, C A, et al.
Publicado: (2011)

Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases
por: Kapel, Nathalie, et al.
Publicado: (2023)

Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?
por: Iordache, Miorita Melina, et al.
Publicado: (2023)

A psychometric analysis of outcome measures in peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2016)

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
por: Machado, Pedro M, et al.
Publicado: (2023)

Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study
por: Jacquemin, Charlotte, et al.
Publicado: (2017)

Serum biomarkers confirming stable remission in inflammatory bowel disease
por: Kessel, Christoph, et al.
Publicado: (2021)

Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis
por: Romero-López, José Pablo, et al.
Publicado: (2021)

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
por: Hromadová, Dominika, et al.
Publicado: (2021)

The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity
por: Lee, Yang Woon, et al.
Publicado: (2019)

Is fecal calprotectin always normal in children with irritable bowel syndrome?
por: Choi, You Jin, et al.
Publicado: (2019)

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
por: Maksymowych, Walter P, et al.
Publicado: (2016)

Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
por: Turina, Maureen C, et al.
Publicado: (2014)

Does faecal calprotectin differentiate between inflammatory bowel disease colitis and non-inflammatory bowel disease colitides?
por: Khalil, Ahmed F., et al.
Publicado: (2020)

Disability and participation in breast and bowel cancer screening in England: a large prospective study
por: Floud, S, et al.
Publicado: (2017)

Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening
por: Raine, Rosalind, et al.
Publicado: (2016)

Predictors of repeat participation in the NHS bowel cancer screening programme
por: Lo, S H, et al.
Publicado: (2015)

Assessing the impact of blood pressure in the development of inflammatory bowel disease
por: Xu, Xia, et al.
Publicado: (2022)

Evaluation of a service intervention to improve awareness and uptake of bowel cancer screening in ethnically-diverse areas
por: Shankleman, J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3d10p03e9n2n0q5cj1ke5tp448